February 12, 2018
Apple to Bring EMR to Smartphones, Making it Easier for Patients to Share Info About their Healthcare and Aid Research
The report that Apple will develop applications to download access of our personal electronic medical record to our personal smart phones ( Apple, in Sign of Health Ambitions, Adds Medical Records Feature for iPhone, NY Times) could be transformational for medical care, our sense of medical wellbeing, and for innovations in medical research. HIPAA (Health Insurance Portability and Accountability Act (HIPAA) of 1996) is an incredible logistic barrier to medical research. The well-intended privacy protections of HIPAA fly in the face of the need to aggregate information for individual and collective benefit. 

To download, review and share our own medical record implies the ability to share this information with medical researchers. This could be a watershed for the field of medical informatics, and practice-changing for cancer patients: EMR data sharing for cancer genetic patterns; EMR sharing for benefits and toxicities of new cancer treatments; use of EMR data sharing to understand the value of new treatments that could allow the FDA to approve and review new cancer drugs more quickly and reduce drug costs; and EMR data sharing to assemble patterns of cancer care, quality and prevention will improve coordination and reduce errors. All of these from the simple and logical conclusion on the part of Apple to make our medical record available for research - through us!

Cleveland Clinic Researchers Uncover How Cancer Stem Cells Drive Triple-Negative Breast Cancer
Cleveland Clinic researchers have published findings in Nature Communications [ Thiagarajan, Nat Commun, 2018] on a new stem cell pathway that allows a highly aggressive form of breast cancer - triple-negative breast cancer - to thrive.

Hormone therapy for breast cancer blocks cancer cells from interacting with hormones such as estrogen and progesterone, which fuel the cancer cells to grow and spread. However, triple-negative breast cancer cells lack the receptors needed to bind to these hormones and growth factors. Without such receptors, typical therapy does not work, contributing to poor survival rates for women with this subtype of breast cancer.
Cleveland Clinic  Lerner Research Institute researchers believe that an aggressive population of cancer cells, called cancer stem cells, is at the heart of why many cancers, including triple-negative breast cancer, are challenging to treat. Cancer stem cells self-replicate, rapidly grow and spread, and change their phenotype in response to the tumor environment.
Ofer Reizes Lathia, Justin The new study, led by Case Comprehensive Cancer Center Members  Justin Lathia, PhD, and Ofer Reizes, PhD, identifies a never-before described survival pathway in cancer stem cells that may serve as a potential target for new triple-negative breast cancer therapies.   more>
University Hospitals Recruits Top Scientist to Lead Research at UH Seidman Cancer Center
Quintin Pan, PhD University Hospitals recently announced the recruitment of one of the nation's leading scientists, Quintin Pan, PhD.

Pan joins University Hospitals as deputy director for research at UH Seidman Cancer Center and professor of medicine at Case Western Reserve University School of Medicine.

He will focus on translational cancer research ranging from novel target identification and drug discovery, to pre-clinical validation and human clinical trials. In particular, his laboratory has elucidated key insights regarding genetic determinants of cancer that provide the foundation for novel therapies to treat aggressive head and neck cancers.

"UH Seidman Cancer Center is so fortunate to have recruited a scientist of Dr. Pan's caliber into our cancer program," said Ted Teknos, MD, Deputy Director for the Seidman Cancer Center, Case Comprehensive Cancer Center and President and Scientific Director, UH Seidman Cancer Center. "His passion for discovery, collaborative spirit and scientific creativity are unparalleled. I look forward to working closely with him and our Case Comprehensive Cancer Center colleagues to set the standard for team science and discovery." more>
Gerds and Nazha Selected as HemOnc Today Next Gen Innovators
Aziz Nazha Aaron GerdsCase Comprehensive Cancer Center members Aaron T. Gerds, MD, MS and  Aziz Nazha, MD were recently nominated into the inaugural class of HemOnc Today Next Gen Innovators.  

According HemOnc Today, " Next Gen Innovators are a highly select group of early career hematologists and oncologists who have advanced their field through innovative approaches in the clinical and research settings." Candidates were nominated by the HemOnc Today Editorial Board and other leaders in the field. 

Additional HemOnc Today Next Gen Innovators will be announced in the spring. Submit nominations to Editorial Director Mark Leiser at mleiser@healio.com.
Cancer Center Seminar Series
February 16, 2018 | Wolstein 1-413
CCSS Lee B flyer - 2018Feb16
Click image to view larger.
Join us Friday, February 16 at noon in Wolstein Research Building Room 1-413 for the weekly Cancer Center Seminar Series to hear Byron Lee, MD, PhD, Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Joint Staff, Department of Urology, Glickman Urologic & Kidney Institute and Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic, discuss " Chromatin modifier gene mutations in urothelial carcinoma." 

Dr. Lee is a member of the GU Malignancies Program of the Case Comprehensive Cancer Center, and has an active urologic oncology practice where he sees patients with bladder cancer, kidney cancer, and testis cancer. His laboratory research focuses on understanding how genomic and epigenetic alterations contribute to the development of bladder cancer, its progression, and its response to therapy. He is also actively developing both patient derived models and novel transgenic animal models of bladder cancer.
Case CCC Clinical Research Retreat
Feb 27, 2018 | Wolstein Research Building
Registration is open for the next Case Comprehensive Cancer Center Clinical Research Retreat, Tuesday, Feb 27 from 5-7p in the Wolstein Research Building.

Retreat themes:

"Implicit bias, cultural humility, and appropriate communication with racial/ethnic minority cancer patients"
Presented by  Monica Webb Hooper, PhD Director, Office of Cancer Disparities Research Case CCC

"Accrual of patients of minority race and ethnicity: The provider's role"
Presented by Smitha Krishnamurthi, MD, Associate Professor, Hematology and Medical Oncology, CWRU/Cleveland Clinic; Member, Case CCC

1.5 CME Category 2 hours and 4 CRECs will be offered to attendees. Pre-registration is required. Parking passes will be provided. 

Contact Mary Wright (maw143@case.edu) with questions. 
CANCER CENTER SCIENTIFIC SERIES: Research Innovation Fund Pilot Projects
Mar 1, 2018 | 5-7 p | Wolstein Research Bldg

We invite you to join us as fellow Case CCC researchers present the findings  of their Research Innovation Fund Pilot Projects. Researchers will offer an overview of their scientific discoveries and outlines of what comes next for their projects. Presentations will be followed by a reception.

Jill Barnholtz-Sloan, PhD Jill Barnholtz-Sloan, PhD 
Sally S. Morley Designated Professor in Brain Tumor Research; Associate Director for Bioinformatics and Member, Case CCC
"Profiles of protein heterogeneity and invasiveness in glioblastoma"

Scacheri, Peter Peter Scacheri, PhD 
Professor, Genetics and Genome Sciences, CWRU; Member, Case CCC
"Targeting metastasis in osteosarcoma by inhibiting tissue factor" 

William Schiemann Bill Schiemann, PhD 
Isador Goodman-Ruth Goodman Blum Professor in Cancer Research; Member, Case CCC
"Regulation of breast cancer metastasis and dormancy by the lncRNA BORG"

Bingcheng Wang, PhD 
Co-Leader and Member, Molecular Oncology Program, Case CCC 
"Targeting EphA2-HSP27 signaling axis in glioblastoma"
2nd Annual Cancer Disparities Symposium
Mar 23, 2018 | Wolstein Research Building
The Case Comprehensive Cancer Center and Office of Cancer Disparities Research will host the " 2nd Annual Cancer Disparities Symposium: Taking it to the Streets: Where Cancer Disparities Research and Community Intersect," on  Friday, March 23, 2018
This event will showcase cutting-edge research, with a focus on reducing and eliminating disparities in cancer, going from bench-to-bedside-to-community and back. This important symposium will also feature two keynote addresses, including a key leader in our community, and an internationally-recognized cancer disparities researcher. We will promote the exchange of ideas and collaborative opportunities among scientists, clinicians, government, and community representatives.

This event is FREE to attend, but pre-registration is required. 

  • Two keynote presentations, by a nationally-recognized researcher and a community leader.
  • Exciting and thought-provoking sessions organized around 2 themes:
    • Structural and Social Determinants
    • Cancer Disparities Across Populatons
  • Poster session highlighting academic research and community programs
  • Networking session
  • All attendee forum
Scientific Keynote
Community Keynote
Lucile Adams-Campbell

Lucile L. Adams-Campbell, PhD
Associate Director, Minority Health and Health Disparities Research, Georgetown University Lombardi Comprehensive Cancer Center
Frances Mills 
Frances Mills, MA OCPSII
Director, Cleveland Office of Minority Health, Cleveland Department of Public Health

NCCN Annual Conference
Mar 22-24, 2018 | Orlando, FL
The NCCN 23rd Annual Conference is just about 7 weeks away .   Don't miss out on the Early Bird Discount--it expires Monday, February 12, 2018. 

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,600 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas.
Midwest DNA Repair Symposium
May 5-6, 2018 | Thwing Center
The Case Comprehensive Cancer Center and Case Western Reserve University will host the 20th Annual Midwest DNA Repair Symposium May 5-6, 2018 . This symposium is a great opportunity for people working on DNA damage and repair in the midwest area to gather together and discuss science! The agenda promises exciting science and opportunities for networking, poster presentations, and keynote presentations from field experts  Stephen Kowalczykowski and Lee Zou

Call for Abstracts
The 20th Annual Midwest DNA Repair Symposium will feature oral and poster presentations.  All graduate students, postdocs, research technician, faculty and fellows conducting related research are invited to submit abstracts. Monetary Prizes will be awarded.

Abstracts must be 500 words or less and fit on an 8 ½ x 11" paper with 1" margins on all sides. Please use Arial 11 font. 

Include the title and authors at the top, acknowledgements at the bottom. You may include figures or illustrations, but they must fit on the same page as the abstract text.  Please indicate whether you prefer oral or poster presentation.

Abstract submission deadline is Monday, April 2 at 5pm to maw143@case.edu
Cancer Stem Cells 2018
Aug 6-8, 2018 | Tinkham Veale University Center
The Cancer Stem Cell Conference (CSC 2018), hosted by the Case Comprehensive Cancer Center and National Center for Regenerative Medicine, is designed to bring together individuals working in the field of cancer stem cell research. CSC 2018 will feature renowned keynote speakers and leaders in the field. This conference is guaranteed to have cutting edge research from a variety of niches within the field.

Registration will open soon - watch this newsletter for updates! 
Pilot Projects for RNAi Screening
DEADLINE: February 26, 2018
The Case Comprehensive Cancer Center is providing collaborative support for projects that focus on the use of RNAi-based screens to identify novel mechanisms underlying cancer biology. RNA-targeted screens have proven to be an effective approach for identifying new pathways involved in cancer initiation, progression, and therapeutic resistance. To facilitate the adoption of such methodologies by its members, the Case CCC will support new projects to be conducted in collaboration with the Small Molecule Drug Development Shared Resource. The Case CCC will supply the requested targeted RNAi library through the screening core and assume screening core costs. Awardees will be expected to commit substantial effort of a lab member to facilitate development of an assay, validate hits, and generate mechanistic data (supported by funds from the Case CCC member). Proposals should be focused on innovative questions, identify a proposed targeted and arrayed RNAi library (full-genome libraries are not responsive to the RFA), describe a feasible high-throughput assay, and have a clear plan for validation of hits. A plan for future analyses of identified candidate genes is also expected, but not specifically supported by this RFA.

Full instructions are posted on the Case CCC website.
AACR Announces AACR-Johnson & Johnson Lung Cancer Innovation Science Grants
DEADLINE Mar 2, 2018, 1p
The  American Association for Cancer Research  (AACR) has announced the launch of the  AACR-Johnson & Johnson Lung Cancer Innovation Science Grants  to stimulate research aimed at eradicating this malignancy. This new funding opportunity, which is supported by the Johnson & Johnson Lung Cancer Initiative, is intended to ignite scientific innovation and transformational advances against lung cancer.

Grant applications will be accepted from multi-institutional teams, composed of principal investigators from at least two, but no more than three, different institutions. The recipients will formally accept the grants at the AACR Annual Meeting 2018, to be held April 14-18 in Chicago.
Cancer Center Summer Training for Medical Students
DEADLINE: Mar 16, 2018
The Case Comprehensive Cancer Center is looking for medical students interested in summer research opportunities.

There are 9 openings available, with 5 supported by the Brian Werbel Memorial Fund and 4 by the Case Comprehensive Cancer Center.
  • Completed application and reference letter due by: Friday, March 16, 2018
  • Awardees must be conducting cancer research with a Case Comprehensive Cancer Center member. View list of members.
  • Those receiving the Brian Werbel Memorial Fund awards must attend the annual golf outing.
Contact Damian Junk ( damian.junk@case.edu) with any questions.
PILOT PROJECT GRANTS: American Cancer Society IRG Awards
Letter of Intent Deadline: Apr 2, 2018
Application Deadline: Apr 16, 2018
  • Pilot funding for CANCER-RELATED research in basic, clinical, prevention & control, behavioral, health services and epidemiology.
  • Up to $30,000 award.
  • Applications accepted for general cancer-related projects and for special interest projects in adolescent-and-young-adult cancer research.
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (usually assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but do not currently hold such a cancer-related grant.

Recipients of IRG pilot project grants must be, at the time of the application, citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application. 

Full instructions are posted on the Case CCC website
Parade - Jan 26, 2018
Screenings have long been a routine part of prevention for many types of cancer. But evidence is showing that across-the-board testing might not be beneficial.
"It's a balance of benefits and harms," says Cleveland Clinic pulmonologist Peter Mazzone, MD, who co-authored new lung cancer screening guidelines with the American College of Chest Physicians for low-dose chest CT scans. The new recommendation saves screening for those most at risk...Tracking your family health history can help you develop a more effective cancer prevention plan. "We always suggest talking about your history when your family gathers," says Charis Eng, MD, chair of Cleveland Clinic's Genomic Medicine Institute and director of the Center for Personalized Genetic Healthcare. "You can write it down or draw a picture of the family tree, and if a relative isn't sure about a particular relative, you can follow up."
NIH BULLETIN- Notices and Funding Opportunities
Program Announcements
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional (PAR-18-605)

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional(PAR-18-606)

Methods Development in Natural Products Chemistry (R41/R42 Clinical Trial Not Allowed)(PAR-18-608)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)(PAR-19-611)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)(PAR-18-612)

Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (U01 Clinical Trial Optional)(PAR-18-616)


Request for Information (RFI): Research Questions to Inform Development of the All of Us Research Program (NOT-OD-18-127)

Notice of ORIP's Interest to Highlight Resource-Related Research Projects for Development of Animal Models and Related Materials that Address High Priority HIV/AIDS-related Research (NOT-OD-18-132)

Notice of Correction to Key Dates to PAR-18-361, "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)"(NOT-CA-18-052)

Notice of Pre-Application Webinar for PAR-18-583 "Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)"(Notice of Pre-Application Webinar for PAR-18-583 "Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)"(NOT-RM-18-013)
Tues, Feb 13
Immunology Research Seminar
Mark Kaplan, PhD Indiana University "Development and function of IL-9- secreting T cells"
12p WRB 1-413

Cancer Biology Seminar Series
Gaelle Muller-Greven Graduate Student, Gladson Lab, Cancer Biology, Cleveland Clinic "Glioma stem-like cell survival is affected by their macropinocytic uptake and targeted trafficking of bevacizumab"
2p NC1-202

Department of Neurosciences
Ajai Tripathi, PhD
Ranjan Dutta lab, Cleveland Clinic
"Role of microRNAs in maturation of oligodendrocytes progenitor cells"
4p NE1-205
Wed, Feb 14
Neurosciences Seminar
Tatiana V. Byzova, PhD
Robert Canova Chair in Angiogenesis Research, Staff, Lerner Research Institute, Cleveland Clinic
"Mechanosensory function of microglia in vascular development and disease"
10a NE1-205

PRCHN Seminar

Elaine Borawski, PhD, PRCHN Executive Director
Angela Bowen Williamson, Professor of Community Nutrition, CWRU IMPACT Study Team
"Ideas moving parents & adolescents to change together (IMPACT) study findings"
12p PRCHN Ground Floor Conference Room
Thurs, Feb 15
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
1p SOM W203
Fri, Feb 16
Taussig Cancer Institute Grand Rounds
Bhumika Patel, MD Cleveland Clinic "Future of clinical genomics in myeloid neoplasms"
9a CA5-120

Cancer Center Seminar Series
Byron Lee, MD, PhD
Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Joint Staff, Department of Urology, Glickman Urological & Kidney Institute and Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic
Member, GU Malignancies Program, Case CCC
" Chromatin modifier gene mutations in urothelial carcinoma"
12p WRB 1-413
Mon, Feb 19
Pathology Research Seminar Series
Nathaniel Robinson "Telomere maintenance mechanisms regulate metastatic progression in breast cancer"
12p WRB 1-413

Cancer Center Research Chalk Talk
Eli Bar, PhD
Assistant Professor, Neurological Surgery, CWRU
Member, Molecular Oncology Program, Case CCC
1p WRB 3-136
Tues, Feb 20
THOR Seminar
Steve Chung, MD Leukemia Service, Memorial Sloan Kettering Cancer Center
"Less Can Be More: Novel insights into hematologic malignancies revealed in rare stem cell populations"
1p NE1-205

Cancer Center Research in Progress 
3p 3-136

Cancer Drug Discovery and Resistance
Eli Bar, PhD
Assistant Professor, Neurological Surgery, CWRU
3p Wearn 137

Neurosciences Seminar
Qingyuan Fan, MD, PhD
Riqiang Yan lab, Cleveland Clinic
"Enhanced neurogenesis by CX3CL1 C-terminal fragment reverses neurodegeneration in Alzheimer's mouse models"
4p NE1-205
Wed, Feb 21
Immunology Faculty Research in Progress
Anna Valujskikh, PhD
Staff, Immunology, Cleveland Clinic
"Wipe the Slate Clean: Can we reshape T cell memory with lymphoablation?"
12p  NC1-202
Thurs, Feb 22
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology
Zach Troyer
Tilton lab, CWRU "Nanoscale Particles as Protein Delivery Vehicles"
John Tilton
"Insights into HIV biology from flow cytometric analysis of viruses ("flow virometry")

1p SOM W203

Neurosciences Seminar
Bryan Luikart, PhD
Associate Professor, Molecular and Systems Biology, Geisel School of Medicine, Dartmouth
"Understanding the neurobiological basis of autism using PTEN as a genetic model"
1p NE1-205
Fri, Feb 23
Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series
Jiaoti Huang, MD, PhD Professor and Chairman, Pathology, Duke University School of Medicine
"The role of cellular heterogeneity in therapeutic resistance and disease progression of prostate cancer" 
12p WRB 1-413


Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065